Recently, the company has also leased a clinical manufacturing facility in Santa Monica, California. The expansion of the manufacturing capabilities will help the firm to support the development
The deal will see the two companies supply panels of antibodies to develop bispecific antibody products using Genmab’s DuoBody platform technology. If a product candidate is developed for
The research alliance will focus on GI sensory and motor mechanisms underlying functional bowel disorders and GI motility disorders. The University’s Neurogastroenterology Group aims to understand the neuromuscular
As part of the deal, J-Network has an exclusive one-year renewable license for the marketing and sales of TRGM’s proprietary product, designed to improve sleep and immune function,
The company focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nanoparticulates, drug/device combination products, solid solutions
According to the company, the initial indications for AMPLEX and PREFIX to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively. The two products are
Resolaris is being developed as a first-in-class intravenous protein therapeutic to treat rare myopathies with an immune component. The drug represents the company’s first Physiocrine-based product candidate in
In June 2006, Revlimid plus dexamethasone was approved for use in multiple myeloma patients who have received at least one prior therapy. The approval of Revlimid was based
Under the deal, Teva will be responsible for all US commercial activities for the product including promotion and distribution, while Eagle’s responsibility include securing all regulatory approvals, conducting
The research collaboration and license agreement will see new small-molecule therapies directed against the nuclear hormone receptors called ROR gamma (t) to treat these disorders. As part of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.